Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes.

Journal of virological methods - 1 Nov 2008

Van Laethem Kristel, Schrooten Yoeri, Covens Kris, Dekeersmaeker Nathalie, De Munter Paul, Van Wijngaerden Eric, Van Ranst Marc, Vandamme Anne-Mieke

Abstract excerpt

Recently, the Food and Drug Administration (FDA) of the USA approved the first integrase inhibitor for inclusion in treatment regimens of HIV-1 patients failing their current regimens with multi-drug resistant strains. However, treatment failure has been observed during integrase inhibitor-contai...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Complementary
Share to Drug Resistance, Viral
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Pyrrolidinones

Share to Raltegravir Potassium

Share to RNA, Viral

Source

Identifiers

PMID: 18706932
DOI: 10.1016/j.jviromet.2008.07.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18706932-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes.PMID 18706932Read ↗

A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes.Semantic proximity Read ↗

Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.Semantic proximity Read ↗

Molecular characterization of 39 HIV isolates representing group M (subtypes A-G) and group O: sequence analysis of gag p24, pol integrase, and env gp41.Semantic proximity Read ↗

Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.Semantic proximity Read ↗

Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.Semantic proximity Read ↗

HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.Semantic proximity Read ↗

Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase InhibitorsSemantic proximity Read ↗

Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure.Semantic proximity Read ↗

The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays.Semantic proximity Read ↗

Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors.Semantic proximity Read ↗

HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.Semantic proximity Read ↗

Analysis of HIV-1 integrase genotypes and polymorphisms among integrase inhibitors-based antiretroviral treatment naïve patients in South Sudan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.